Antibiotics Market Analysis By Drug Class, By Mechanism Of Action And Segment Forecasts To 2024

  • ID: 3972875
  • Report
  • 119 pages
  • Grand View Research
1 of 4
The antibiotics market is expected to reach USD 57.0 billion by 2024. Rising prevalence of infectious diseases especially in developing regions such as Asia Pacific and MEA is anticipated to contribute towards market growth.

More than 15.0% of the deaths, in children below the age of five, are estimated to be due to pneumonia and according to the statistics provided by the WHO about 9.2 million deaths were recorded in 2015. Similar to tuberculosis, the highest prevalence of the disease is identified to be in the South Asian and Sub-Saharan regions. Currently, the required antibiotic treatment is available only to one third of the infected population, thereby increasing the disease burden.

Government reforms specific to antibiotics such as the Generating Antibiotics Incentives Now (GAIN) Act in the U.S. are projected to help market growth over the forecast period. This further expected facilitate development of advanced drugs.

On the contrary, uncertain regulatory policies are likely to hinder the growth of this vertical impacting market growth significantly. In 2013, the U.S. FDA revised the guidance for registration trials for drugs used in the treatment of acute bacterial skin and skin structure infections. The guidance states the use of short term measures of anti-infective efficacy (percent reduction in lesion size at 48 to 72 hours) as opposed to long term measures such as resolution of infection at 10-14 days, which is termed as Test to Cure or TOC.

Further Key Findings From the Study Suggest:

Antibiotic segment including tetracyclines, imidazoles, lincosamides and monoclonal antibodies held commanding share in 2015 and are also anticipated to grow at a lucrative growth rate over the forecast period

Development of monoclonal antibodies for antibiotic resistant microorganism is key highlight of this segment. Increasing incidences of pneumonia, blood stream infections, and urinary tract infections (UTI) are anticipated to foster the usage of carbapenems class of antibiotics.

Cell wall synthesis inhibitors dominated the mechanism outlook in 2015. Majority of the antibiotics such as penicillins, cephalosporins and carbapenems forms the cell wall synthesis inhibitor class.

RNA synthesis inhibitors as well as folic acid synthesis inhibitors are anticipated to witness healthy growth over the forecast period. Development of several antiviral drugs which inhibit transcription and reverse transcription process are anticipated to support the growth. Folic acid inhibitor sulfa drugs are anticipated to grow as they have wide application scope.

Asia Pacific on account of huge population base, high prevalence of infectious diseases, regulation reforms and greater usage of generic medicine held commanding share in 2015.

Latin America, especially Brazil with strong growth in pharmaceutical sector is also projected to exhibit remunerative growth. Outbreak of certain viruses such as Ebola in African region also contributed towards the significant growth of MEA region.

Some of the key players in this vertical are Pfizer, Inc., Janssen Pharmaceuticals, Abbott, GlaxoSmithKline plc, Sanofi, Novartis AG, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company and Astellas Pharma, Inc.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

Chapter 1 Research Methodology
1.1 Information procurement
1.2 Data Analysis

Chapter 2 Executive Summary

Chapter 3 Market Snapshot

Chapter 4 Market Variables, Trends & Scope
4.1 Market segmentation & scope
4.1.1 Market Driver Analysis
4.1.1.1 Development of advanced products
4.1.1.2 Increasing prevalence of` infectious diseases
4.1.1.3 Rising collaborative development efforts
4.1.2 Market Restraint Analysis
4.1.2.1 Uncertain regulatory policies
4.1.2.2 High R&D cost
4.1.2.3 Development of resistance against antibiotics
4.2 Penetration & growth prospect mapping
4.3 Antibiotics  – SWOT Analysis, By Factor (political & legal, economic and technological)
4.4 Industry Analysis – Porter’s

Chapter 5 Market Categorization 1: Mechanism Estimates & Trend Analysis
5.1 Antibiotics market: Mechanism movement analysis
5.2 Cell wall synthesis inhibitors
5.2.1 Cell wall synthesis inhibitors market, 2013 – 2024 (USD Million)
5.3 Protein synthesis inhibitors
5.3.1 Protein synthesis inhibitors market, 2013 – 2024 (USD Million)
5.4 DNA synthesis inhibitors
5.4.1 DNA synthesis inhibitors market, 2013 – 2024 (USD Million)
5.5 RNA synthesis inhibitors
5.5.1 RNA synthesis inhibitors market, 2013 – 2024 (USD Million)
5.6 Mycolic acid inhibitors
5.6.1 Mycolic acid inhibitors market, 2013 – 2024 (USD Million)
5.7 Folic acid synthesis inhibitors
5.7.1 Folic acid synthesis inhibitors market, 2013 – 2024 (USD Million)

Chapter 6 Market Categorization 2: Drug Class Estimates & Trend Analysis
6.1 Antibiotics market: Drug class movement analysis
6.1.1 Cephalosporins
6.1.1.1 Cephalosporins market, 2013 – 2024 (USD Million)
6.1.2 Penicillin
6.1.2.1 Penicillin market, 2013 – 2024 (USD Million)
6.1.3 Fluoroquinolones
6.1.3.1 Fluoroquinolones market, 2013 – 2024 (USD Million)
6.1.4 Macrolides
6.1.4.1 Macrolides market, 2013 – 2024 (USD Million)
6.1.5 Carbapenems
6.1.5.1 Carbapenems market, 2013 – 2024 (USD Million)
6.1.6 Aminoglycosides
6.1.6.1 Aminoglycosides market, 2013 – 2024 (USD Million)
6.1.7 Sulfonamides
6.1.7.1 Sulfonamides market, 2013 – 2024 (USD Million)
6.1.8 Other antibiotics
6.1.8.1 Other antibiotics market, 2013 – 2024 (USD Million)

Chapter 7 Market Categorization 6: Regional Estimates & Trend Analysis, by Mechanism and Drug Class
7.1 Antibiotics market share by region, 2015 & 2024
7.2 North America
7.2.1 North America antibiotics market, 2013 – 2024 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. antibiotics market, 2013 – 2024 (USD Million)
7.2.3 Canada
7.3 Europe
7.2.3.1 Canada antibiotics market, 2013 – 2024 (USD Million)
7.3.1 Europe antibiotics market, 2013 – 2024 (USD Million)
7.3.2 UK
7.3.2.1 UK antibiotics market, 2013 – 2024 (USD Million)
7.3.3 Germany
7.3.3.1 Germany antibiotics market, 2013 – 2024 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific antibiotics market, 2013 – 2024 (USD Million)
7.4.2 Japan
7.4.2.1 Japan antibiotics market, 2013 – 2024 (USD Million)
7.4.3 China
7.4.3.1 China antibiotics market, 2013 – 2024 (USD Million)
7.4.4 India
7.4.4.1 India antibiotics market, 2013 – 2024 (USD Million)
7.5 Latin America
7.5.1 Latin America antibiotics market, 2013 – 2024 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil antibiotics market, 2013 – 2024 (USD Million)
7.5.3 Mexico
7.6 MEA
7.5.3.1 Mexico antibiotics market, 2013 – 2024 (USD Million)
7.6.1 MEA antibiotics market, 2013 – 2024 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa antibiotics market, 2013 – 2024 (USD Million)

Chapter 8 Competitive Landscape
8.1 Strategy framework
8.2 Company Profiles
8.2.1 Pfizer, Inc.
8.2.1.1 Company Overview
8.2.1.2 Financial Performance
8.2.1.3 Product Benchmarking 
8.2.1.4 Strategic Initiatives
8.2.2 Janssen Pharmaceuticals 
8.2.2.1 Company Overview 
8.2.2.2 Financial Performance
8.2.2.3 Product Benchmarking
8.2.2.4 Strategic Initiatives
8.2.3 Abbott
8.2.3.1 Company Overview
8.2.3.2 Financial Performance
8.2.3.3 Product Benchmarking
8.2.3.4 Strategic Initiatives
8.2.4 GlaxoSmithKline plc.
8.2.4.1 Company Overview
8.2.4.2 Financial Performance
8.2.4.3 Product Benchmarking
8.2.4.4 Strategic Initiatives
8.2.5 Sanofi
8.2.5.1 Company Overview
8.2.5.2 Financial Performance
8.2.5.3 Product Benchmarking
8.2.5.4 Strategic Initiatives
8.2.6 Novartis AG
8.2.6.1 Company Overview
8.2.6.2 Financial Performance
8.2.6.3 Product Benchmarking
8.2.6.4 Strategic Initiatives
8.2.7 Bayer AG
8.2.7.1 Company Overview
8.2.7.2 Financial Performance (in million)
8.2.7.3 Product Benchmarking
8.2.7.4 Strategic Initiatives
8.2.8 Bristol-Myers Squibb Company
8.2.8.1 Company Overview
8.2.8.2 Financial Performance
8.2.8.3 Product Benchmarking
8.2.8.4 Strategic Initiatives
8.2.9 Eli Lilly and Company
8.2.9.1 Company Overview
8.2.9.2 Financial Performance (in million)
8.2.9.3 Product Benchmarking
8.2.10 Astellas Pharma, Inc.
8.2.10.1 Company Overview
8.2.10.2 Financial Performance
8.2.10.3 Product Benchmarking
8.2.10.4 Strategic Initiatives

List of Tables
Table 1 Antibiotic drugs under Phase III clinical trial, 2015
Table 2 Public-private and Private-private agreements:
Table 3 North America antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 4 North America antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 5 North America antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 6 North America antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 7 U.S. antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 8 U.S. antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 9 U.S. antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 10 U.S. antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 11 Canada antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 12 Canada antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 13 Canada antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 14 Canada antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 15 Europe antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 16 Europe antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 17 Europe antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 18 Europe antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 19 UK antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 20 UK antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 21 UK antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 22 UK antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 23 Germany antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 24 Germany antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 25 Germany antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 26 Germany antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 27 Asia Pacific antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 28 Asia Pacific antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 29 Asia Pacific antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 30 Asia Pacific antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 31 Japan antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 32 Japan antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 33 Japan antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 34 Japan antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 35 China antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 36 China antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 37 China antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 38 China antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 39 India antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 40 India antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 41 India antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 42 India antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 43 Latin America antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 44 Latin America antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 45 Latin America antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 46 Latin America antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 47 Brazil antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 48 Brazil antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 49 Brazil antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 50 Brazil antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 51 Mexico antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 52 Mexico antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 53 Mexico antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 54 Mexico antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 55 MEA antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 56 MEA antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 57 MEA antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 58 MEA antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 59 South Africa antibiotics market estimates, by mechanism, 2013 - 2015 (USD Million)
Table 60 South Africa antibiotics market forecasts, by mechanism, 2016 - 2024 (USD Million)
Table 61 South Africa antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)
Table 62 South Africa antibiotics market estimates, by drug class, 2013 - 2015 (USD Million)

List of Figures
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary, USD Million
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 14 Porter’s Five Forces Analysis
FIG. 15 Antibiotics market mechanism outlook key takeaways
FIG. 16 Antibiotics market: Mechanism movement analysis
FIG. 17 Cell wall synthesis inhibitors market, 2013 – 2024 (USD Million)
FIG. 18 Protein synthesis inhibitors market, 2013 – 2024 (USD Million)
FIG. 19 DNA synthesis inhibitors market, 2013 – 2024 (USD Million)
FIG. 20 RNA synthesis inhibitors market, 2013 – 2024 (USD Million)
FIG. 21 Mycolic acid inhibitors market, 2013 – 2024 (USD Million)
FIG. 22 Folic acid synthesis inhibitors market, 2013 – 2024 (USD Million)
FIG. 23 Antibiotics market drug class outlook key takeaways
FIG. 24 Antibiotics market: Drug class movement analysis
FIG. 25 Cephalosporins market, 2013 – 2024 (USD Million)
FIG. 26 Penicillin market, 2013 – 2024 (USD Million)
FIG. 27 Fluoroquinolones market, 2013 – 2024 (USD Million)
FIG. 28 Macrolides market, 2013 – 2024 (USD Million)
FIG. 29 Carbapenems market, 2013 – 2024 (USD Million)
FIG. 30 Aminoglycosides market, 2013 – 2024 (USD Million)
FIG. 31 Sulfonamides market, 2013 – 2024 (USD Million)
FIG. 32 Other antibiotics market, 2013 – 2024 (USD Million)
FIG. 33 Regional market place: Key takeaways
FIG. 34 Regional outlook, 2015 & 2024
FIG. 35 North America antibiotics market, 2013 – 2024 (USD Million)
FIG. 36 U.S. antibiotics market, 2013 – 2024 (USD Million)
FIG. 37 Canada antibiotics market, 2013 – 2024 (USD Million)
FIG. 38 Europe antibiotics market, 2013 – 2024 (USD Million)
FIG. 39 UK antibiotics market, 2013 – 2024 (USD Million)
FIG. 40 Germany antibiotics market, 2013 – 2024 (USD Million)
FIG. 41 Asia Pacific antibiotics market, 2013 – 2024 (USD Million)
FIG. 42 Japan antibiotics market, 2013 – 2024 (USD Million)
FIG. 43 China antibiotics market, 2013 – 2024 (USD Million)
FIG. 44 India antibiotics market, 2013 – 2024 (USD Million)
FIG. 45 Latin America antibiotics market, 2013 – 2024 (USD Million)
FIG. 46 Brazil antibiotics market, 2013 – 2024 (USD Million)
FIG. 47 Mexico antibiotics market, 2013 – 2024 (USD Million)
FIG. 48 MEA antibiotics market, 2013 – 2024 (USD Million)
FIG. 49 South Africa antibiotics market, 2013 – 2024 (USD Million)
FIG. 50 Strategy framework

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll